Glycotope receives regulatory approval for GlycoExpress Technology and initiates clinical trial with antibody GT-MAB 2.5-GEX

27-Nov-2009 - Germany

Glycotope GmbH, has received regulatory approval by Germany and Italian regulatory authorities for a Phase I study of Glycotope´s lead antibody GT-MAB 2.5-GEXTM for the treatment of various solid cancers. The approvals further underline the suitability of Glycotope´s proprietary GlycoExpressTM technology for the improvement, glycooptimization and high yield production of therapeutic proteins for the use in humans.

“The approval of GT-MAB 2.5-GEX as well as the regulatory approval of the GlycoExpress production technology based on its glycoengineered human cell lines represents a significant milestone for the company” says Steffen Goletz, PhD, Founder, CEO and CSO of Glycotope. “After generating very encouraging data in pre-clinical studies, we are now looking forward to demonstrate the importance of glycosylation in the clinic by generating a substantial benefit to patients.”

The Phase I study will evaluate the safety and tolerability of GT-MAB 2.5-GEXTM in a broad series of cancer indications.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

AMRI promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing

AMRI Hires Director of In Vitro Biology in Singapore

Action Pharma reports positive results in a proof of concept phase IB study in obese human volunteers treated with AP1030

Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist - Company Anticipates Initiating Phase 2a Studies by Early 2012

Elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board

Galapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeutics

Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor

RIKEN: Discovery of DNA Silencing Mechanism Reveals How Plants Protect Their Genome

Novasep invests EUR 30 million to build world's largest chromatography plant for the pharmaceutical industry - New plant on its Mourenx, France site to produce a large volume commercial API

Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy - £10m in milestone payments received from GlaxoSmithKline

KINAXO Biotechnologies receives 1 million EUR funding to quantify drug interactions with cellular protein targets

Effectiveness of drug to improve natriuretic peptide levels for chronic heart failure